AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.00880-06v1
51/3/941    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barchiesi, F.
Right arrow Articles by Scalise, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barchiesi, F.
Right arrow Articles by Scalise, G.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2007, p. 941-945, Vol. 51, No. 3
0066-4804/07/$08.00+0     doi:10.1128/AAC.00880-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Caspofungin in Combination with Amphotericin B against Candida parapsilosis{triangledown}

Francesco Barchiesi,1* Elisabetta Spreghini,1 Serena Tomassetti,1 Daniele Giannini,2 and Giorgio Scalise1

Istituto di Malattie Infettive e Medicina Pubblica,1 Centro di Gestione Presidenza Medicina e Chirurgia, Università Politecnica delle Marche, Ancona, Italy2

Received 17 July 2006/ Returned for modification 28 November 2006/ Accepted 30 November 2006

Candida parapsilosis has emerged as an important nosocomial pathogen. In the present study, a checkerboard broth microdilution method was performed to investigate the in vitro activities of caspofungin (CAS) in combination with amphotericin B (AMB) against three clinical isolates of C. parapsilosis. Although there was a significant reduction of the MIC of one or both drugs used in combination, an indifferent interaction (fractional inhibitory concentration index greater than 0.50 and less than or equal to 4.0) was observed in 100% of cases. This finding was confirmed by killing curve studies. By a disk diffusion assay, the halo diameters produced by antifungal agents in combination were often significantly greater than those produced by each drug alone. Antagonism was never observed. In a murine model of systemic candidiasis, CAS at either 0.25 or 1 mg/kg/day combined with AMB at 1 mg/kg/day was significantly more effective than each single drug at reducing the colony counts in kidneys. Higher doses of the echinocandin (i.e., 5 and 10 mg/kg/day) combined with the polyene did not show any advantage over CAS alone. Overall, our study showed a positive interaction of CAS and AMB against C. parapsilosis.

* Corresponding author. Mailing address: Istituto di Malattie Infettive e Medicina Pubblica, Università Politecnica delle Marche, Azienda, Ospedaliero-Universitaria, Ospedali Riuniti Umberto I°-Lancisi-Salesi, Via Conca, 60020 Torrette, Ancona, Italy. Phone: 39 0715963467. Fax: 39 0715963468. E-mail: l.infettive{at}ao-umbertoprimo.marche.it.

{triangledown} Published ahead of print on 11 December 2006.

Antimicrobial Agents and Chemotherapy, March 2007, p. 941-945, Vol. 51, No. 3
0066-4804/07/$08.00+0     doi:10.1128/AAC.00880-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2007 by the American Society for Microbiology. All rights reserved.